PPD Inc.
Austin, Texas, 78744, United States
NCT Number: NCT07146191
The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers. This study will quantify drug and metabolites in blood, urine, and feces samples collected before study drug administration and through at least 168 hours after SC dosing of [14C]-RE104.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Austin, Texas, 78744, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single, subcutaneous dose of 2-[14C]-RE104 for Injection
Time frame: Through 168 hours postdose
Time frame: Through 168 hours postdose
Time frame: Through 168 hours postdose
Time frame: Through 168 hours postdose
Time frame: Through 168 hours postdose
Time frame: Through 168 hours postdose
Time frame: Through 168 hours postdose
Time frame: Through 168 hours postdose
Time frame: Through 168 hours postdose
Time frame: Through 168 hours postdose
Time frame: Through 168 hours postdose
Time frame: From dosing (Day 0) through study completion (Day 7)
A treatment-emergent adverse event (TEAE) is defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a study drug.
Reunion Neuroscience Inc
Industry
A Phase 1, Open-label, Single Period Study to Evaluate the Absorption, Metabolism, and Excretion of a Single Microdose of [14C]-RE104 in Healthy Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07406464
Healthy Participant Study
Ghent, Oost-Vlaanderen, Belgium
View Trial DetailsNCT07572513
Blood Glucose, GLP-1
West Lafayette, Indiana, United States
View Trial DetailsNCT07421778
Healthy Participant Study
Groningen, Netherlands
View Trial DetailsNCT07304791
Healthy Participant Study, Healthy Subjects
London, United Kingdom
View Trial Details